PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.87%
Positive revenue growth while Healthcare median is negative. Peter Lynch might see a relative strength advantage in a tough sector.
12.17%
Gross profit growth of 12.17% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
54.90%
EBIT growth exceeding 1.5x Healthcare median of 4.48%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
49.18%
Operating income growth exceeding 1.5x Healthcare median of 3.79%. Joel Greenblatt would see if unique processes drive exceptional profitability.
14.74%
Net income growth exceeding 1.5x Healthcare median of 5.03%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
14.74%
EPS growth exceeding 1.5x Healthcare median of 9.09%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
14.74%
Diluted EPS growth exceeding 1.5x Healthcare median of 9.01%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Healthcare median is 0.23%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Healthcare median is 0.29%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Healthcare median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
149.77%
10Y CAGR of 149.77% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
59.05%
5Y CAGR of 59.05% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
38.14%
3Y CAGR of 38.14% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
199.81%
Net income/share CAGR exceeding 1.5x Healthcare median of 30.04% over a decade. Joel Greenblatt might see a standout compounder of earnings.
61.16%
5Y net income/share CAGR > 1.5x Healthcare median of 21.37%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
30.34%
3Y net income/share CAGR > 1.5x Healthcare median of 12.64%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
318.66%
Equity/share CAGR exceeding 1.5x Healthcare median of 11.12% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
81.97%
5Y equity/share CAGR > 1.5x Healthcare median of 4.42%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
35.33%
Positive short-term equity/share CAGR while Healthcare is negative. Peter Lynch finds a relative advantage vs. sector-level slowdown.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.30%
AR growth of 3.30% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
0.78%
Inventory growth of 0.78% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
1.69%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
2.49%
Positive BV/share change while Healthcare median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-21.26%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
5.14%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.